Literature DB >> 12069613

Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides.

Hélène G Bazin1, Marcos A Marques, Albert P Owens, Robert J Linhardt, Keith A Crutcher.   

Abstract

Apolipoprotein E (apoE) has been genetically linked to late-onset Alzheimer's disease (AD). The role of this lipid-transport protein in AD remains to be established. One hypothesis is that apoE, particularly the apoE4 isoform, may have neurotoxic effects as demonstrated using apoE-related synthetic peptides and the N-terminal fragment of apoE. ApoE is a heparan-sulfate binding protein, and apoE peptide neurotoxicity can be blocked by heparin and prevented by degrading heparan sulfate or inhibiting its biosynthesis. The possibility that heparin inhibition of toxicity is mediated by a specific oligosaccharide sequence was investigated using a bioassay to determine the inhibition of apoE peptide toxicity by glycosaminoglycans and purified glycosaminoglycan oligosaccharides. Studies on modified heparins showed that the presence of N-sulfo groups and either 2- or 6-O sulfo groups were required for inhibition of toxicity. Heparin oligosaccharides with eight or more saccharide residues with seven O-sulfo groups and four N-sulfo groups exhibited potent inhibition. Larger oligosaccharides, and heparin and heparan sulfate polymers, afforded comparable, or somewhat better, protective effects but also caused clumping and detachment of cells when administrated alone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069613     DOI: 10.1021/bi025817e

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Dromedary glycosaminoglycans: molecular characterization of camel lung and liver heparan sulfate.

Authors:  Mohammad Warda; Robert J Linhardt
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2005-11-17       Impact factor: 2.231

2.  Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance.

Authors:  Kristin I Stanford; Lianchun Wang; Jan Castagnola; Danyin Song; Joseph R Bishop; Jillian R Brown; Roger Lawrence; Xaiomei Bai; Hiroko Habuchi; Masakazu Tanaka; Wellington V Cardoso; Koji Kimata; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

3.  Expression of human liver HSPGs on acute myeloid leukemia.

Authors:  Preeyanat Vongchan; Robert J Linhardt
Journal:  Clin Immunol       Date:  2006-10-10       Impact factor: 3.969

4.  Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease.

Authors:  Marcos A Marques; Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

5.  Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study.

Authors:  Yuko Yamauchi; Noriko Deguchi; Chika Takagi; Masafumi Tanaka; Padmaja Dhanasekaran; Minoru Nakano; Tetsurou Handa; Michael C Phillips; Sissel Lund-Katz; Hiroyuki Saito
Journal:  Biochemistry       Date:  2008-06-24       Impact factor: 3.162

6.  Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2.

Authors:  Preeyanat Vongchan; Robert J Linhardt
Journal:  World J Hepatol       Date:  2017-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.